LEADER 05044nam  2200745Ia 450 
001 9910877682203321
005 20200520144314.0
010   $a1-280-36642-7
010   $a9786610366422
010   $a0-470-35636-7
010   $a0-471-45930-5
010   $a0-471-21881-2
035   $a(CKB)111087027125452
035   $a(EBL)159848
035   $a(SSID)ssj0000190028
035   $a(PQKBManifestationID)11199400
035   $a(PQKBTitleCode)TC0000190028
035   $a(PQKBWorkID)10166602
035   $a(PQKB)11227877
035   $a(MiAaPQ)EBC159848
035   $a(OCoLC)85820000
035   $a(EXLCZ)99111087027125452
100   $a20011119d2002      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aLC/MS applications in drug development /$fMike S. Lee
210   $aNew York $cJ. Wiley & Sons$dc2002
215   $a1 online resource (257 p.)
225 1 $aWiley-Interscience series on mass spectrometry
300   $aDescription based upon print version of record.
311   $a0-471-40520-5 
320   $aIncludes bibliographical references (p. 205-234) and index.
327   $aLC/MS APPLICATIONS IN DRUG DEVELOPMENT; CONTENTS; Preface; Acknowledgments; 1. Introduction; Emerging Analytical Needs; Integration of LC/MS into Drug Development; Partnerships and Acceptance; Overview; 2. Drug Development Overview; Analysis Perspectives; The Four Stages of Drug Development; Drug Discovery; Preclinical Development; Clinical Development; Manufacturing; 3. Accelerated Drug Development; Accelerated Development Strategies; Quantitative and Qualitative Process Elements; Quantitative Process Pipeline; Qualitative Process Pipeline; Motivating Factors
327   $aAnalysis Opportunities for Accelerated DevelopmentFull-Time Equivalent; Sample Throughput Model; Elimination Model; Rate-Determining Event Model; Accelerated Development Perspectives; 4. LC/MS Development; The Elements of LC/MS Application; HPLC; Mass Spectrometry; LC/MS Interface; LC/MS Growth; 5. Strategies; Standard Methods; Template Structure Identification; Databases; Screening; Integration; Miniaturization; Parallel Processing; Visualization; Automation; Summary; 6. LC/MS Applications; Drug Discovery; Proteomics; Protein Expression Profiling; Quantitation; Glycoprotein Mapping
327   $aNatural Products DereplicationLead Identification Screening; Bioaffinity Screening; Combinatorial Library Screening; Open-Access LC/MS; Structure Confirmation; High Throughput; Purification; Combinatorial Mixture Screening; In Vivo Drug Screening; Pharmacokinetics; In Vitro Drug Screening; Metabolic Stability Screening; Membrane Permeability; Drug-Drug Interaction; Metabolite Identification; Preclinical Development; Metabolite Identification; Impurity Identification; Degradant Identification; Clinical Development; Quantitative Bioanalysis-Selected Ion Monitoring
327   $aQuantitative Bioanalysis-Selected Reaction MonitoringQuantitative Bioanalysis-Automated Solid-Phase Extraction; Quantitative Bioanalysis-Automated On-Line Extraction; Metabolite Identification; Degradant Identification; Manufacturing; Impurity Identification Using Data-Dependent Analysis; Peptide Mapping in Quality Control; Patent Protection; 7. Future Applications and Prospects; Workstations; Multidimensional Analysis; Miniaturization; Information Management; Strategic Outsourcing; Summary; 8. Perspectives on the Future Growth of LC/MS; 9. Conclusions; Glossary; References; Index
330   $aBreakthroughs in combinatorial chemistry and molecular biology, as well as an overall industry trend toward accelerated development, mean the rate of sample generation now far exceeds the rate of sample analysis in the pursuit of producing new and better pharmaceuticals. LC/MS is an analytical tool that helps the researcher identify the most promising sample early in the selection process, effectively creating a shortcut to finding new drugs. This book is the first to describe LC/MS applications within the context of drug development, including the discovery, preclinical, clinical, and manufac
410  0$aWiley-Interscience series on mass spectrometry.
606   $aDrug development$xMethodology
606   $aDrugs$xAnalysis
606   $aLiquid chromatography
606   $aMass spectrometry
606   $aCombinatorial chemistry
606   $aGel permeation chromatography
606   $aDrugs$xTesting$xMethodology
615  0$aDrug development$xMethodology.
615  0$aDrugs$xAnalysis.
615  0$aLiquid chromatography.
615  0$aMass spectrometry.
615  0$aCombinatorial chemistry.
615  0$aGel permeation chromatography.
615  0$aDrugs$xTesting$xMethodology.
676   $a615.19
676   $a615/.19
700   $aLee$b Mike S.$f1960-$01593247
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910877682203321
996   $aLC$94190634
997   $aUNINA